Lakefront Biotherapeutics (LKFT) Non-Current Assets (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Non-Current Assets for 13 consecutive years, with $354.7 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets fell 43.29% year-over-year to $354.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $354.7 million (down 43.29% YoY) and the FY2025 annual result came in at $372.2 million, down 8.59% from the prior year.
• Non-Current Assets slipped to $354.7 million in Q1 2026 per LKFT's latest filing, from $372.2 million in the prior quarter.
• Over the last five years, Non-Current Assets for LKFT reached as high as $697.3 million in Q3 2024 and fell as low as $354.7 million in Q1 2026.
• A 5-year average of $506.8 million and a median of $542.7 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 50.16% — and 2026, when it sank 43.29%.
• Year by year, Non-Current Assets stood at $566.1 million in 2022, then sank by 34.91% to $368.5 million in 2023, then gained by 10.5% to $407.2 million in 2024, then slipped by 8.59% to $372.2 million in 2025, then dropped by 4.7% to $354.7 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $354.7 million, $372.2 million, and $398.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.